Wall Street analysts expect DexCom, Inc. (NASDAQ:DXCM) to announce earnings of $0.06 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for DexCom’s earnings, with the highest EPS estimate coming in at $0.22 and the lowest estimate coming in at ($0.08). DexCom reported earnings per share of ($0.05) during the same quarter last year, which suggests a positive year over year growth rate of 220%. The company is scheduled to report its next earnings report on Wednesday, May 6th.
On average, analysts expect that DexCom will report full year earnings of $1.79 per share for the current financial year, with EPS estimates ranging from $1.02 to $2.64. For the next fiscal year, analysts anticipate that the firm will report earnings of $2.58 per share, with EPS estimates ranging from $2.07 to $3.43. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow DexCom.
DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.41. DexCom had a positive return on equity of 16.16% and a negative net margin of 12.68%. The firm had revenue of $462.80 million for the quarter, compared to the consensus estimate of $457.00 million.
DXCM has been the topic of a number of recent research reports. Bank of America reaffirmed a “buy” rating and set a $250.00 price objective (up from $220.00) on shares of DexCom in a research note on Wednesday, December 18th. Morgan Stanley raised their target price on DexCom from $202.00 to $225.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Raymond James raised their price objective on shares of DexCom from $258.00 to $288.00 and gave the stock an “outperform” rating in a report on Friday. BidaskClub lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, January 18th. Finally, Guggenheim lifted their target price on shares of DexCom from $245.00 to $300.00 and gave the company a “buy” rating in a report on Friday. Seven research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. DexCom currently has a consensus rating of “Buy” and a consensus price target of $253.56.
In other news, Director Barbara Kahn sold 9,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $205.14, for a total value of $1,846,260.00. Following the transaction, the director now directly owns 2,613 shares of the company’s stock, valued at $536,030.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $221.37, for a total transaction of $2,213,700.00. The disclosure for this sale can be found here. Insiders sold 47,427 shares of company stock worth $10,539,425 in the last quarter. Company insiders own 0.88% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. TCI Wealth Advisors Inc. increased its position in shares of DexCom by 1,475.0% during the fourth quarter. TCI Wealth Advisors Inc. now owns 126 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 118 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of DexCom by 54.8% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 178 shares of the medical device company’s stock valued at $39,000 after purchasing an additional 63 shares in the last quarter. Steward Partners Investment Advisory LLC grew its holdings in shares of DexCom by 33.3% in the third quarter. Steward Partners Investment Advisory LLC now owns 280 shares of the medical device company’s stock valued at $41,000 after purchasing an additional 70 shares in the last quarter. Neo Ivy Capital Management acquired a new position in shares of DexCom in the third quarter valued at approximately $54,000. Finally, FinTrust Capital Advisors LLC acquired a new position in DexCom during the 4th quarter worth approximately $59,000. 97.85% of the stock is currently owned by institutional investors.
DXCM traded up $31.70 during trading on Friday, reaching $283.91. The stock had a trading volume of 2,945,041 shares, compared to its average volume of 742,415. The stock has a market cap of $22.41 billion, a PE ratio of -145.59 and a beta of 0.80. The company has a debt-to-equity ratio of 1.41, a quick ratio of 5.26 and a current ratio of 5.63. DexCom has a one year low of $107.44 and a one year high of $254.70. The business has a 50-day moving average of $233.01 and a 200-day moving average of $189.89.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: Why do companies engage in swaps?
Get a free copy of the Zacks research report on DexCom (DXCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.